Qin X - Search Results

1

Gut mycobiome: A promising target for colorectal cancer.

Qin X, Gu Y, Liu T, Wang C, Zhong W, Wang B, Cao H. Qin X, et al. Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188489. doi: 10.1016/j.bbcan.2020.188489. Epub 2020 Dec 3. Biochim Biophys Acta Rev Cancer. 2021. PMID: 33278512 Review.

2

The Potential Role of Gut Mycobiome in Irritable Bowel Syndrome.

Gu Y, Zhou G, Qin X, Huang S, Wang B, Cao H. Gu Y, et al. Among authors: qin x. Front Microbiol. 2019 Aug 21;10:1894. doi: 10.3389/fmicb.2019.01894. eCollection 2019. Front Microbiol. 2019. PMID: 31497000 Free PMC article. Review.

3

Gut Microbiota-Derived Metabolites in Colorectal Cancer: The Bad and the Challenges.

Zhang W, An Y, Qin X, Wu X, Wang X, Hou H, Song X, Liu T, Wang B, Huang X, Cao H. Zhang W, et al. Among authors: qin x. Front Oncol. 2021 Oct 18;11:739648. doi: 10.3389/fonc.2021.739648. eCollection 2021. Front Oncol. 2021. PMID: 34733783 Free PMC article. Review.

4

Bile acid-gut microbiota crosstalk in irritable bowel syndrome.

Gu Y, Li L, Yang M, Liu T, Song X, Qin X, Xu X, Liu J, Wang B, Cao H. Gu Y, et al. Among authors: qin x. Crit Rev Microbiol. 2023 May;49(3):350-369. doi: 10.1080/1040841X.2022.2058353. Epub 2022 Apr 7. Crit Rev Microbiol. 2023. PMID: 35389754 Review.

5

Saccharomyces boulardii, a yeast probiotic, inhibits gut motility through upregulating intestinal serotonin transporter and modulating gut microbiota.

Gu Y, Wang C, Qin X, Zhou B, Liu X, Liu T, Xie R, Liu J, Wang B, Cao H. Gu Y, et al. Among authors: qin x. Pharmacol Res. 2022 Jul;181:106291. doi: 10.1016/j.phrs.2022.106291. Epub 2022 Jun 8. Pharmacol Res. 2022. PMID: 35690329

6

Lactobacillus rhamnosus GG supernatant promotes intestinal mucin production through regulating 5-HT4R and gut microbiota.

Gu Y, Qin X, Zhou G, Wang C, Mu C, Liu X, Zhong W, Xu X, Wang B, Jiang K, Liu J, Cao H. Gu Y, et al. Among authors: qin x. Food Funct. 2022 Nov 28;13(23):12144-12155. doi: 10.1039/d2fo01900k. Food Funct. 2022. PMID: 36326009

7

Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling.

Zhang W, Qin X, Zhang K, Ma J, Li M, Jin G, Liu X, Wang S, Wang B, Wu J, Liu T, Zhong W, Cao H. Zhang W, et al. Among authors: qin x. Cell Oncol (Dordr). 2024 Aug;47(4):1183-1199. doi: 10.1007/s13402-024-00920-2. Epub 2024 Feb 5. Cell Oncol (Dordr). 2024. PMID: 38315283

8

Selection strategy of second-line biologic therapies in adult patients with ulcerative colitis following prior biologic treatment failure: Systematic review and meta-analysis.

Zhang H, Mu C, Gu Y, Meng F, Qin X, Cao H. Zhang H, et al. Among authors: qin x. Pharmacol Res. 2024 Apr;202:107108. doi: 10.1016/j.phrs.2024.107108. Epub 2024 Feb 24. Pharmacol Res. 2024. PMID: 38403257 Free article.

9

Gut microbiota and metabolites as predictors of biologics response in inflammatory bowel disease: A comprehensive systematic review.

Wang C, Gu Y, Chu Q, Wang X, Ding Y, Qin X, Liu T, Wang S, Liu X, Wang B, Cao H. Wang C, et al. Among authors: qin x. Microbiol Res. 2024 May;282:127660. doi: 10.1016/j.micres.2024.127660. Epub 2024 Feb 28. Microbiol Res. 2024. PMID: 38442454 Review.

10

Correction to: Microbial metabolite trimethylamine-N-oxide induces intestinal carcinogenesis through inhibiting farnesoid X receptor signaling.

Zhang W, Qin X, Zhang K, Ma J, Li M, Jin G, Liu X, Wang S, Wang B, Wu J, Liu T, Zhong W, Cao H. Zhang W, et al. Among authors: qin x. Cell Oncol (Dordr). 2024 Aug;47(4):1201-1204. doi: 10.1007/s13402-024-00937-7. Cell Oncol (Dordr). 2024. PMID: 38625668 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

9,813 results

Search Page

Filters